Company profile - Canadian Company Capabilities

Third-Party Information Liability Disclaimer

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Arbutus Biopharma

Legal/Operating Name:

Arbutus Biopharma

Company Contact Information:

http://www.arbutusbio.com

info@arbutusbio.com

Tel.: (604) 419-3200

Fax: (604) 419-3201

Mailing Address:

100-8900 Glenlyon Parkway
BURNABY, British Columbia
V5J 5J8

Location Address:

100-8900 Glenlyon Parkway
BURNABY, British Columbia
V5J 5J8

Logo

Logo

Company Profile


Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). Tekmira's three lead RNAi product candidates target cholesterol management, cancer and Ebola infection. In addition to its pipeline of products, Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Pfizer, Takeda, Bristol-Myers Squibb, and Merck.
Full profile

Full profile

Ian Mortimer
Title:
Vice President
Area of Responsibility:
Management Executive.
Telephone:
(604) 419-3200
Facsimile:
(604) 419-3201
Email:
imortimer@tekmirapharm.com

top of page

Country of Ownership:
Canada  
Year Established:
2008
Exporting:
Yes  
Primary Industry (NAICS):
325410 - Pharmaceutical and Medicine Manufacturing
Alternate Industries (NAICS):
541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity:
Manufacturer / Processor / Producer  
Number of Employees:
85 
Service Name:
Development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi)

top of page

As the fields of genetics, medicine and therapeutics continue to converge, the management of illness at its genetic source by silencing genes via RNA interference (RNAi) holds the very real potential to revolutionize treatment on a scale not seen in decades. Tekmira is one of a handful of biotech companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.

Tekmira is uniquely equipped to become a force in this field. Guided by a cohesive vision, the Company possesses leading technology capabilities and a solid intellectual property portfolio in the area of using lipid nanoparticle (LNP) technology to deliver siRNA (small interfering RNA) as well as other nucleic acids in the treatment of disease.

With two RNAi drug candidates in clinical development and another in preclinical development, Tekmira is well positioned to aggressively advance its product strategy. In addition, Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Pfizer, Takeda, Bristol-Myers Squibb, and Merck.

Finally, broad manufacturing capabilities and a strong capital position permit the Company to move forward decisively and build a solid base for both near and longer term growth.

Industry sector market interests:

  • Medical/Biotechnology/Chemical

top of page

Third-Party Information Liability Disclaimer

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Contacts

Contact information

Ian Mortimer
Title:
Vice President
Area of Responsibility:
Management Executive.
Telephone:
(604) 419-3200
Facsimile:
(604) 419-3201
Email:
imortimer@tekmirapharm.com
Description

Company description

Country of Ownership:
Canada  
Year Established:
2008
Exporting:
Yes  
Primary Industry (NAICS):
325410 - Pharmaceutical and Medicine Manufacturing
Alternate Industries (NAICS):
541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity:
Manufacturer / Processor / Producer  
Number of Employees:
85 
Products, services and licensing

Product / Service / Licensing

Service Name:
Development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi)
Technology

Technology profile

As the fields of genetics, medicine and therapeutics continue to converge, the management of illness at its genetic source by silencing genes via RNA interference (RNAi) holds the very real potential to revolutionize treatment on a scale not seen in decades. Tekmira is one of a handful of biotech companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.

Tekmira is uniquely equipped to become a force in this field. Guided by a cohesive vision, the Company possesses leading technology capabilities and a solid intellectual property portfolio in the area of using lipid nanoparticle (LNP) technology to deliver siRNA (small interfering RNA) as well as other nucleic acids in the treatment of disease.

With two RNAi drug candidates in clinical development and another in preclinical development, Tekmira is well positioned to aggressively advance its product strategy. In addition, Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Pfizer, Takeda, Bristol-Myers Squibb, and Merck.

Finally, broad manufacturing capabilities and a strong capital position permit the Company to move forward decisively and build a solid base for both near and longer term growth.
Market

Market profile

Industry sector market interests:

  • Medical/Biotechnology/Chemical
Last Update Date 2017-02-24
Date Modified: